Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Most diagnostic tests for tuberculosis (TB) rely on sputum samples, which are difficult to obtain and have low sensitivity in immunocompromised patients, patients with disseminated TB, and children, delaying treatment initiation. The World Health Organization (WHO) calls for the development of a rapid, biomarker-based, non-sputum test capable of detecting all forms of TB at the point-of-care to enable immediate treatment initiation. Lipoarabinomannan (LAM) is the only WHO-endorsed TB biomarker that can be detected in urine, an easily collected sample. This status update discusses the characteristics of LAM as a biomarker, describes the performance of first-generation urine LAM tests and reasons for slow uptake, and presents considerations for developing the next generation of more sensitive and impactful tests. Next-generation urine LAM tests have the potential to reach adult and pediatric patients regardless of HIV status or site of infection and facilitate global TB control. Implementation and scale-up of existing LAM tests and development of next-generation assays should be prioritized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
The South African tuberculosis care cascade: Estimated losses and methodological challenges
Naidoo, P., Theron, G., Rangaka, M. X., Chihota, V. N., Vaughan, L., Brey, Z. O., & Pillay, Y. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix335 · Cited by 238 · cited 1×
“Analyses of country‐level data in South Africa have shown losses of approximately 12% between diagnosis and treatment initiation, which could potentially be diminished by POC testing [61,62].”
BackgroundGupta-Wright, A., Corbett, E. L., van Oosterhout, J. J., Wilson, D., Grint, D., Alufandika-Moyo, M., Peters, J. A., Chiume, L., Flach, C., Lawn, S. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31267-4 · Cited by 213 · cited 1×
“The second RCT (STAMP trial, [29]) enrolled HIV‐positive adults from two hospitals in Malawi and South Africa and found overall 8‐ week mortality occurred in 21% of the SOC arm and 18% in the LAM group; an adjusted risk reduction of ‐2.”
BackgroundBjerrum, S., Schiller, I., Dendukuri, N., Kohli, M., Nathavitharana, R. R., Zwerling, A. A., Denkinger, C. M., Steingart, K. R., & Shah, M. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011420.pub3 · Cited by 186 · cited 6×
“Based on these meta-analysis results [21], the WHO announced updated guidelines for use of AlereLAM in 2019, which are summarized in Table 2 [42].”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Bulterys, M. A., Wagner, B., Redard-Jacot, M., Suresh, A., Pollock, N. R., Moreau, E., Denkinger, C. M., Drain, P. K., & Broger, T.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2019-12-31
- Volume
- 9
- Issue
- 1
- Pages
- 111
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W2998321752
- Cited by
- 162
- References
- 4
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update. https://app.cochat.ai/papers/10.3390/jcm9010111
- The paper
- Bulterys, M. A., Wagner, B., Redard-Jacot, M., Suresh, A., Pollock, N. R., Moreau, E., Denkinger, C. M., Drain, P. K., & Broger, T. (2019). Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update. Journal of Clinical Medicine. https://doi.org/10.3390/jcm9010111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.